Lung Cancer Non-Small Cell Cancer (NSCLC) Recruiting Phase 2 Trials for Ipilimumab (DB06186)

Also known as: Non - Small Cell Lung Cancer NSCLC / Carcinoma, Non-Small-Cell Lung / Non-Small-Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma / Nonsmall Cell Lung Cancer / Lung Cancer(NSCLC) / Non-Small Cell Lung Cancer / Non-Small-Cell Lung Cancer (NSCLC) / NSCLC (Non-Small Cell Lung Cancer) / Non Small Cell Lung Cancer (NSCLC) / Lung Cancer (Non-Small Cell) / NSCLC, Non Small Cell Lung Cancer / Non-small Cell Lung Cancers / Lung Cancer, Nonsmall Cell / Non-Small Cell Lung Carcinoma / Lung Cancer Non-Small Cell / Non-Small-Cell Lung Cancer / Non-Small Cell Lung Cancer (NSCLC) / Non Small Cell Lung Cancer / Non-Small Cell Lung Carcinoma (NSCLC) / Carcinoma, Non-Small Cell Lung / Lung Cancer, Non-Small Cell / Non Small-cell Lung Cancer / NSCLC Non-small Cell Lung Cancer / NSCLC / Non Small Cells Lung Cancer / Non-Small Cell Lung Cancer(NSCLC) / Non- Small Cell Lung Cancer / Lung Cancer - Non Small Cell / Lung Cancer (NSCLC) / Non Small Cell Lung Cancer NSCLC / Non-Small-Cell-Lung Cancer (NSCLC) / Non-Small-Cell-Lung Cancer / Non-small cell lung cancer (disorder) / Non-small cell lung cancer NOS

IndicationStatusPhase
DBCOND0046916 (Lung Cancer Non-Small Cell Cancer (NSCLC))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03573947Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLCTreatment
NCT03158129Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung CancerTreatment
NCT03285321Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)Treatment
NCT03091491Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung CancerTreatment
NCT03001882An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)Treatment
NCT03262779Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.Treatment